Photo from wikipedia
I was pleased to read the article by Kaneko and colleagues1 on the efficacy and safety of tocilizumab in patients with adult-onset Still’s disease, because the current information on its… Click to show full abstract
I was pleased to read the article by Kaneko and colleagues1 on the efficacy and safety of tocilizumab in patients with adult-onset Still’s disease, because the current information on its biologic efficacy has been mainly obtained from small retrospective case series and not from prospective randomised trials. The authors have presented a randomised controlled trial in which they suggest that tocilizumab is effective in adult-onset Still’s disease refractory to glucocorticoid …
Keywords:
onset still;
adult onset;
disease refractory;
tocilizumab patients;
patients adult;
still disease
Journal Title: Annals of the Rheumatic Diseases
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Annals of the Rheumatic Diseases
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!